Summary of Immunome Conference Call Company Overview - **Company**: Immunome - **Focus**: Targeted oncology with a pipeline of differentiated products, including first-in-class and best-in-class therapies [2][3] Key Product: Varegacestat - **Description**: An oral gamma secretase inhibitor for treating desmoid tumors, with a once-daily dosing regimen [3][4] - **Clinical Data**: - Phase 3 RINGSIDE study showed: - 84% reduction in risk of progression (hazard ratio of 0.16) - 56% objective response rate - 83% median best tumor volume reduction [3][6] - **NDA Submission**: Planned for Q2 2026, with no anticipated roadblocks [4][10] - **Market Potential**: - Estimated 10,000-11,000 patients in the U.S. with desmoid tumors, with only 10% currently on gamma secretase inhibitors [9][22] - Potential to capture a significant share of the market, with a target of 3,000 patients translating to a billion-dollar annual revenue [22] Competitive Landscape - **Nirogacestat**: The only approved systemic therapy for desmoid tumors, approved in late 2023. Varegacestat offers a better pharmacokinetic profile and once-daily dosing compared to Nirogacestat [5][9] - **Market Dynamics**: - OGSIVEO's launch has faced challenges, potentially limiting market growth. Immunome aims to differentiate by emphasizing the benefits of varegacestat [22][23] ADC Portfolio - **Technology**: Immunome is developing a proprietary ADC payload (HC74) to overcome limitations of existing ADCs, such as therapeutic window and resistance pathways [10][13] - **Current ADCs**: - **IM-1021**: ROR1-targeted ADC in dose escalation, focusing on lymphoma [11][12] - **Upcoming ADCs**: Three additional ADCs expected to enter clinical trials in 2026, all utilizing HC74 technology [16][17] - **Market Strategy**: Emphasis on selecting appropriate targets and optimizing ADC design to enhance efficacy and reduce toxicity [34][35] Radiotherapy Program - **IM-3050**: FAP-targeted radiotherapy with an active IND, expected to dose the first patient soon [17][48] - **Market Opportunity**: FAP is expressed in 75% of solid tumors, presenting a significant potential market [48] Financial and Commercial Strategy - **Cost-effective Launch**: Plans for a lean commercial infrastructure with approximately 32-35 sales reps, focusing on maximizing patient benefit and adherence [28][29] - **Long-term Vision**: Immunome aims to build a comprehensive portfolio of breakthrough oncology therapies, with varegacestat as the first clinical success [17][49] Conclusion - **Investment Outlook**: Immunome is currently valued primarily on varegacestat, with significant potential for the ADC portfolio to contribute to future growth [49]

Immunome Corporate Presentation 44th Annual J.P. Morgan Healthcare Conference 1 January 2026 Disclaimer and Forward-Looking Statements Forward-Looking Statements Statements in this presentation that are not purely historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "vision," "objective," "anticipate," "believe," "estimate," "predic ...

Key Highlights of SpringWorks Therapeutics - OGSIVEO (nirogacestat) is the first and only FDA-approved therapy for desmoid tumors[15] - GOMEKLI (mirdametinib) is the first and only FDA-approved therapy for both adults and children with NF1-PN[15] - SpringWorks Therapeutics expects profitability in the first half of 2026[10] - SpringWorks Therapeutics had $461.9 million in cash, cash equivalents, and marketable securities[132] OGSIVEO (Nirogacestat) for Desmoid Tumors - OGSIVEO generated $61.5 million in net revenue in Q4 2024 and $172.0 million in FY 2024[15] - Between October 2023 and October 2024, approximately 11,000 patients with desmoid tumor ICD-10 claims were identified[15] - Objective response rate (ORR) increased from 34.3% with up to 1 year of treatment to 45.7% with up to 4 years of treatment[48] GOMEKLI (Mirdametinib) for NF1-PN - GOMEKLI is approved for the treatment of adult and pediatric patients 2 years of age and older with NF1-PN[10] - The U S market includes approximately 30,000 adult and 10,000 pediatric patients with NF1-PN[15] - In clinical trials, GOMEKLI showed a confirmed overall response rate of 41% in adults (n=58) and 52% in pediatrics (n=56)[67]

Summary of Relay Therapeutics Conference Call Company Overview - **Company**: Relay Therapeutics (Ticker: RLAY) - **Event**: BofA Annual Healthcare Conference - **Date**: May 14, 2025 Key Industry Insights - **Focus on Precision Oncology**: The company has faced challenges in precision oncology and is now prioritizing its PI3K program for breast cancer, indicating a strategic shift in resource allocation towards this program [2][4] - **Restructuring and Cost Management**: Relay Therapeutics has made significant reductions in its research footprint due to limited access to capital, focusing on maximizing value from its balance sheet over the next three to five years [4][5] Financial Position - **Cash Reserves**: The company currently holds $710 million in cash, which is expected to sustain operations and support studies through 2029 [5] Clinical Development - **PI3K Alpha Program**: The PI3K alpha immune selective molecule (02/1400) is identified as a key driver for the company, with plans to advance through pivotal studies [5][9] - **Upcoming Studies**: The company is preparing for the Rediscover II Phase III study, with expectations of presenting updated data at the upcoming ASCO conference [9][10] - **Vascular Malformation Study**: A new study has been initiated for a PIK3CA mutant-driven genetic disease, with an estimated 170,000 patients in the U.S. [6][53] Competitive Landscape - **Benchmarking Against Competitors**: The company is comparing its clinical data against competitors, noting that its median progression-free survival (PFS) is significantly better than the competitive benchmark of 5.5 months [12][14] - **Differentiation Strategy**: Relay Therapeutics aims to establish a next-generation profile compared to existing therapies, emphasizing the importance of being first to market in a large patient population [19][20] Regulatory Considerations - **Potential Labeling Strategies**: The company is considering the evolving landscape of CDK4/6 therapies and aims to construct studies that could lead to line-agnostic approvals [21][23] Market Opportunity - **Vascular Malformations Market**: The potential market for PIK3CA-driven vascular malformations is significant, with estimates suggesting that 10-40% of patients may seek systemic therapy, translating to a meaningful commercial opportunity [53][54] Future Directions - **Ongoing Research**: The company plans to advance its Fabry and NRAS programs to IND readiness, with decisions on further development contingent on the macro environment and business considerations [57] Additional Notes - **Safety and Efficacy**: The company believes that its experience in oncology has de-risked safety profiles for its new indications, allowing for a more favorable assessment of efficacy in younger patient populations [43][44] - **Strategic Focus**: Relay Therapeutics is maintaining a small research footprint focused on high-value oncology targets while exploring additional preclinical programs as opportunities arise [57]